Pete Goss Comments on Pradaxa Preemption Ruling to Law360

Pete Goss provided insight to Law360 for a story on a Connecticut ruling that failure-to-warn claims involving the blood thinner Pradaxa were preempted by FDA regulations. The ruling is significant for its application of the U.S. Supreme Court’s guidance in Merck Sharp & Dohme Corp. v. Doris Albrecht. 

"There won't necessarily be the level of deference you would get with a pure factual finding, but this is a really detailed analysis that I think the court of appeals would give some serious consideration to."PETE GOSS